ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia
Go back to ORYZON Initiates Patient Enrollment in IDEAL Phase II Trial of Iadademstat in Essential Thrombocythemia| ORION MARINE GROUP, Inc. (NYSE: ORN) | Delayed: 15.56 -0.04 (0.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.60 | 52 Week High | $9.48 | |||
| Open | $15.12 | 52 Week Low | $3.25 | |||
| Day High | $15.89 | P/E | N/A | |||
| Day Low | $14.59 | EPS | $-0.01 | |||
| Volume | 348,886 | |||||
